Intrahepatic Cholangiocarcinoma

Learning Objectives: On successful completion of this activity, participants should be able to (1) describe the status of the current literature regarding new indications for radioembolization; (2) describe standard hepatic vascularization, identify common routes for extrahepatic depositions, and judge when "skeletization" of hepatic arteries could be unnecessary; and (3) appraise the different methods of activity calculation and recognize the strengths and pitfalls of pretreatment and posttreatment dosimetry.Financial Disclosure: Dr. Lam is a consultant/advisor for BTG International and a meeting participant/lecturer for SirTex Medical. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through July 2018.Radioembolization is an established treatment modality that has been subjected to many improvements over the last decade. Developments are occurring at a high pace, affecting patient selection and treatment. The aim of this review is therefore to provide an overview of current practice, with a focus on recent developments in the field of radioembolization. Several practical issues and recommendations in the application of radioembolization will be discussed, ranging from patient selection to treatment response and future applications.

show abstract

“…and cisplatin overall survival is 11.7 mo (72,73). After radioembolization, overall survival of 15.5 mo can be reached (72).…”

Section: Clinical Outcome and Tumor Responsementioning

confidence: 98%

⁹⁰Y Hepatic Radioembolization: An Update on Current Practice and Recent Developments

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Instead, they may present with dull right upper quadrant pain, weight loss, and elevated alkaline phosphatase level, or rarely fever. While a considerable number of patients are asymptomatic, with the lesions detected incidentally during radiologic examinations [43] . Paraneoplastic syndromes are rare findings of patients with ICC, which may present with cutaneous findings such as Sweet syndrome [44] and acanthosis nigricans [45] .…”

Section: Symptoms and Signsmentioning

confidence: 99%